NCT05645536 2026-01-12Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA StudyTolmar Inc.Phase 3 Enrolling by invitation250 enrolled
NCT06603987 2025-11-19Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMAStella Pharma CorporationPhase 1/2 Enrolling by invitation30 enrolled
NCT03328026 2025-02-04Combination Study of SV-BR-1-GM With RetifanlimabBriaCell Therapeutics CorporationPhase 1/2 Enrolling by invitation36 enrolled
NCT06409221 2024-05-10VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition StudyConcrEnrolling by invitation200 enrolled